EUVIMEDEUVIMED entdecken
Crossref

The role of dual-tracer PET imaging with ER and HER2 in patients with metastatic breast cancer: a pilot study

Cheng Liu, Donghui Pan, Yuyun Sun, Xiaoping Xu, Zhongyi Yang, Min Yang, Shaoli Song

Annals of Nuclear Medicine · 2025-10 · 39 (10) · 1113-1123

DOI: 10.1007/s12149-025-02071-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Nuclear Medicine, online erschienen am 26.06.2025. Verfasst von Cheng Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Medical Imaging, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Receptors, Estrogen, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Engineering Research Center of Molecular Imaging Probes Program, Shanghai Municipal Hospital Development Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Accurate and real-time evaluation of tumor ER and HER2 status is essential for improving the clinical management of patients with metastatic breast cancer (MBC). The purpose of this pilot study was to investigate the value of PET imaging with 18F-FES and 68 Ga-HER2 affibody for the noninvasive evaluation of the ER and HER2 status in MBC patients. METHODS: From January 2021 to September 2023, 17 metastatic breast cancer (MBC) patients underwent 1⁸F-FES and ⁶⁸Ga-HER2-affibody PET/CT within one month, with concurrent 1⁸F-FDG PET/CT for tumor glycolytic activity evaluation. The imaging data were integrated to detect lesions and analyze intra-patient heterogeneity. The efficacy of lesion detection across different modalities was evaluated, along with an assessment of their potential impact on clinical decision-making. RESULTS: A total of 174 metastatic lesions were detected: 163 (93.7%) showed high 1⁸F-FDG uptake, 91 (52.3%) exhibited 1⁸F-FES positivity, and 104 (59.8%) demonstrated ⁶⁸Ga-HER2-affibody binding. The biopsy correlation revealed significantly higher 1⁸F-FES and ⁶⁸Ga-HER2-affibody uptake in ER-positive (P < 0.05) and HER2-positive (P < 0.05) lesions, respectively, compared to their negative counterparts. In clinical decision-making influenced by PET findings, 12 of 17 patients (70.6%) had treatment strategies concordant with 1⁸F-FES and ⁶⁸Ga-HER2-affibody PET results. Among nine dual-positive patients (both tracers positive), 55.6% (5/9) were administered combined endocrine therapy and anti-HER2 targeted regimens, thereby obviating chemotherapy. In single-tracer-positive subgroups, 100% (2/2) of 1⁸F-FES + /⁶⁸Ga-HER2 - cases received endocrine therapy (with or without CDK4/6 inhibitors), whereas 66.7% (2/3) of ⁶⁸Ga-HER2 + /1⁸F-FES - patients were treated with anti-HER2 therapy (with or without chemotherapy). Notably, three dual-negative patients were not prescribed antihormonal or anti-HER2 agents; instead, they received chemotherapy (with or without immunotherapy), avoiding inappropriate targeted interventions. CONCLUSION: Dual-tracer PET imaging enables noninvasive assessment of ER/HER2 status and intratumoral heterogeneity, providing critical insights for personalized treatment strategies in MBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenPositron Emission Tomography Computed TomographyHumansPilot ProjectsFemaleMiddle AgedAgedAdultNeoplasm MetastasisGallium RadioisotopesFluorodeoxyglucose F18

Stichwörter der Autor:innen

18F-FES68 Ga-HER2 affibodyERHER2Metastatic breast cancer

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenGallium RadioisotopesFluorodeoxyglucose F18ERBB2 protein, human

Autor:innen und Institutionen

  • Shanghai Institute of Medical Imaging, Shanghai, 200032, China.
  • Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Xuhui District, Shanghai, 200032, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
  • Center for Biomedical Imaging, Fudan University, Shanghai, 200032, China.
  • Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, 200032, China.
  • NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, No. 20, Qianrong Road, Wuxi, 214063, Jiangsu, China.

Förderung

  • National Natural Science Foundation of China
  • Shanghai Engineering Research Center of Molecular Imaging Probes Program
  • Shanghai Municipal Hospital Development Center
  • Shanghai Scientific and Technological Innovation Program

Zitieren

APA

Liu, C., Pan, D., Sun, Y., Xu, X., Yang, Z., Yang, M., & Song, S. (2025). The role of dual-tracer PET imaging with ER and HER2 in patients with metastatic breast cancer: a pilot study. Annals of Nuclear Medicine, 39(10), 1113-1123. https://doi.org/10.1007/s12149-025-02071-2

Vancouver

Liu C, Pan D, Sun Y, Xu X, Yang Z, Yang M, et al. The role of dual-tracer PET imaging with ER and HER2 in patients with metastatic breast cancer: a pilot study. Annals of Nuclear Medicine. 2025;39(10):1113-1123. doi:10.1007/s12149-025-02071-2

BibTeX
@article{Liu2025,
  author = {Liu, Cheng and Pan, Donghui and Sun, Yuyun and Xu, Xiaoping and Yang, Zhongyi and Yang, Min and Song, Shaoli},
  title = {The role of dual-tracer PET imaging with ER and HER2 in patients with metastatic breast cancer: a pilot study},
  journal = {Annals of Nuclear Medicine},
  year = {2025},
  volume = {39},
  number = {10},
  pages = {1113--1123},
  doi = {10.1007/s12149-025-02071-2}
}
Kostenlos starten →